TERN
Company Description
Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and obesity. The company develops TERN-101, a liver-distributed and non-bile acid farnesoid X receptor agonist, which is in Phase IIa clinical trial for the treatment of NASH; and TERN-201, a vascular adhesion protein-1 inhibitor that is in Phase Ib clinical trial for the treatment of NASH. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase I clinical trial for the treatment of NASH; and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for NASH and metabolic diseases, such as obesity. The company was incorporated in 2016 and is headquartered in Foster City, California.
Track Record
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 1.00M | 0 | 0 | 0 |
| Net Income | (96.21M) | (88.85M) | (90.21M) | (60.34M) | (50.16M) | (29.35M) | (68.82M) | (17.71M) |
| EPS | -1.03 | -1.12 | -1.27 | -1.67 | -1.98 | -1.61 | -2.74 | -0.74 |
| Free Cash Flow | (82.18M) | (70.06M) | (67.44M) | (49.38M) | (42.17M) | (30.39M) | (67.12M) | (18.32M) |
| FCF / Share | -0.88 | -0.88 | -0.95 | -1.37 | -1.67 | -1.21 | -2.67 | -0.76 |
| Operating CF | (82.18M) | (70.02M) | (67.39M) | (49.11M) | (41.83M) | (29.81M) | (66.22M) | (18.07M) |
| Total Assets | 1.03B | 363.93M | 268.52M | 287.03M | 168.07M | 92.29M | 23.90M | 89.07M |
| Total Debt | 919,000 | 1.35M | 603,000 | 1.21M | 0 | 12.88M | 0 | 0 |
| Cash & Equiv | 524.75M | 161.44M | 79.93M | 143.24M | 47.70M | 74.85M | 12.33M | 82.52M |
| Book Value | 1.01B | 345.87M | 255.37M | 276.94M | 160.30M | 68.59M | 4.21M | 72.23M |
| Return on Equity | -0.10 | -0.26 | -0.35 | -0.22 | -0.31 | -0.43 | -16.36 | -0.25 |
| Metric | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | (23.57M) | (24.64M) | (24.09M) | (23.91M) | (21.80M) | (21.95M) | (22.74M) | (22.37M) | (21.02M) | (29.77M) | (17.90M) | (21.53M) |
| EPS | -0.24 | -0.27 | -0.26 | -0.26 | -0.24 | -0.28 | -0.31 | -0.30 | -0.29 | -0.42 | -0.25 | -0.31 |
| Free Cash Flow | (19.08M) | (19.77M) | (18.88M) | (24.45M) | (14.58M) | (16.45M) | (16.19M) | (22.83M) | (19.36M) | (20.71M) | (12.99M) | (14.38M) |
| FCF / Share | -0.20 | -0.22 | -0.21 | -0.27 | -0.16 | -0.21 | -0.22 | -0.31 | -0.27 | -0.29 | -0.18 | -0.21 |
| Operating CF | (19.08M) | (19.77M) | (18.88M) | (24.45M) | (14.58M) | (16.45M) | (16.18M) | (22.80M) | (19.32M) | (20.70M) | (12.99M) | (14.38M) |
| Total Assets | 1.03B | 301.65M | 320.42M | 339.31M | 363.93M | 378.23M | 230.88M | 246.77M | 268.52M | 271.69M | 289.70M | 301.29M |
| Total Debt | 919,000 | 1.03M | 1.13M | 1.24M | 1.35M | 1.30M | 249,000 | 427,000 | 603,000 | 770,000 | 876,000 | 1.04M |
| Cash & Equiv | 524.75M | 150.70M | 145.97M | 139.02M | 161.44M | 270.14M | 91.50M | 65.10M | 79.93M | 37.89M | 80.92M | 184.35M |
| Book Value | 1.01B | 284.07M | 305.23M | 326.04M | 345.87M | 364.47M | 218.68M | 236.72M | 255.37M | 258.43M | 274.15M | 287.68M |
| Return on Equity | -0.02 | -0.09 | -0.08 | -0.07 | -0.06 | -0.06 | -0.10 | -0.09 | -0.08 | -0.12 | -0.07 | -0.07 |
